62 Chapter 2 55. Sanford SD, Okuma JO, Pan J, et al: Gender differences in sleep, fatigue, and daytime activity in a pediatric oncology sample receiving dexamethasone. J Pediatr Psychol 33:298-306, 2008 56. Vallance K, Liu W, Mandrell BN, et al: Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer 46:1848-55, 2010 57. Kiive E, Merenakk L, Harro M, et al: Changes in platelet monoamine oxidase activity, cholesterol levels and hyperactive behaviour in adolescents over a period of three years. Neurosci Lett 384:310-5, 2005 58. Soliman A, Udemgba C, Fan I, et al: Convergent Effects of Acute Stress and Glucocorticoid Exposure upon MAO-A in Humans. Journal of Neuroscience 32:17120-17127, 2012 59. Gordijn MS, Rensen N, Gemke RJ, et al: Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev:CD008727, 2015 60. de Kloet ER: From receptor balance to rational glucocorticoid therapy. Endocrinology 155:275469, 2014 61. Buckley TM, Schatzberg AF: On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 90:3106-14, 2005 62. Garcia-Borreguero D, Wehr TA, Larrosa O, et al: Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. Journal of Clinical Endocrinology & Metabolism 85:4201-4206, 2000 63. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-66, 2009 64. Ismail MF, Lavelle C, Cassidy EM: Steroid-induced mental disorders in cancer patients: a systematic review. Future Oncol 13:2719-2731, 2017 65. Yang L, Panetta JC, Cai XJ, et al: Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. Journal of Clinical Oncology 26:1932-1939, 2008 66. Myers RM, Balsamo L, Lu X, et al: A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Cancer 120:1417-25, 2014 67. Steur LMH, Grootenhuis MA, Van Someren EJW, et al: High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatr Blood Cancer:e28165, 2020 68. Sivertsen B, Harvey AG, Pallesen S, et al: Trajectories of sleep problems from childhood to adolescence: a population-based longitudinal study from Norway. J Sleep Res 26:55-63, 2017 69. Kazak AE, Abrams AN, Banks J, et al: Psychosocial Assessment as a Standard of Care in Pediatric Cancer. Pediatr Blood Cancer 62 Suppl 5:S426-59, 2015 70. Kunin-Batson AS, Lu X, Balsamo L, et al: Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. Cancer 122:1608-17, 2016 71. Manenschijn L, van den Akker EL, Lamberts SW, et al: Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 1179:179-98, 2009 72. Spijker AT, van Rossum EF: Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. Ann N Y Acad Sci 1179:199-215, 2009
RkJQdWJsaXNoZXIy MTk4NDMw